Compare AFCG & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AFCG | COCH |
|---|---|---|
| Founded | 2020 | 1995 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Real Estate Investment Trusts | Blank Checks |
| Sector | Real Estate | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.4M | 51.0M |
| IPO Year | 2020 | N/A |
| Metric | AFCG | COCH |
|---|---|---|
| Price | $2.75 | $0.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $4.50 | ★ $6.00 |
| AVG Volume (30 Days) | 83.0K | ★ 292.7K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $24,563,601.00 | N/A |
| Revenue This Year | $1,334.03 | $1.58 |
| Revenue Next Year | $17.33 | N/A |
| P/E Ratio | $5.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.06 | $0.36 |
| 52 Week High | $5.10 | $1.89 |
| Indicator | AFCG | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 43.46 | 52.71 |
| Support Level | $2.49 | $0.63 |
| Resistance Level | $2.78 | $0.74 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 50.00 | 48.35 |
Advanced Flower Capital Inc is an externally managed Maryland corporation that operates as a Business Development Company (BDC). The firm's primary operations involve originating, structuring, underwriting, and managing senior secured loans and other debt securities. Its investment portfolio includes loans to state law-compliant cannabis operators, ancillary cannabis businesses, and middle-market companies in other industries. These loans are typically secured by collateral such as real estate, equipment, cash flows, and license values.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.